152 results on '"Kim, T.M."'
Search Results
2. HLA-corrected tumor mutation burden and homologous recombination deficiency for the prediction of response to PD-(L)1 blockade in advanced non-small-cell lung cancer patients
3. Molecular correlates of response to capmatinib in advanced non-small-cell lung cancer: clinical and biomarker results from a phase I trial
4. Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC
5. Preference for subcutaneous or intravenous administration of rituximab among patients with untreated CD20+ diffuse large B-cell lymphoma or follicular lymphoma: results from a prospective, randomized, open-label, crossover study (PrefMab)
6. Complex chromosomal rearrangements by single catastrophic pathogenesis in NUT midline carcinoma
7. Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: a phase II clinical trial
8. Concomitant ALK translocation and EGFR mutation in lung cancer: a comparison of direct sequencing and sensitive assays and the impact on responsiveness to tyrosine kinase inhibitor
9. Corrigendum to “Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphoma”: [Ann Oncol 35 (2024) 1039-1047]
10. Reply to the Letter to the Editor “Odronextamab against relapsed or refractory follicular lymphoma” by Y. Shimazu
11. 400P Phase I study of fianlimab, a human lymphocyte activation gene-3 (LAG-3) monoclonal antibody, in combination with cemiplimab in advanced melanoma (mel)
12. Primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with non-small-cell lung cancer harboring TKI-sensitive EGFR mutations: an exploratory study
13. Phase II trial of everolimus for the treatment of nonclear-cell renal cell carcinoma
14. Multicenter phase II study of sunitinib in patients with non-clear cell renal cell carcinoma
15. 994P Efficacy and safety of capmatinib plus spartalizumab in treatment-naïve patients with advanced NSCLC harboring MET exon 14 skipping mutation
16. 988P Phase I/II study of mobocertinib in EGFR exon 20 insertion (ex20ins) + metastatic NSCLC (mNSCLC): Updated results from platinum-pretreated patients (PPP)
17. 790MO Phase I study of fianlimab, a human lymphocyte activation gene-3 (LAG-3) monoclonal antibody, in combination with cemiplimab in advanced melanoma (mel)
18. 1194TiP AdvanTIG-205: Phase II trial of ociperlimab (OCI) + tislelizumab (TIS) + chemotherapy (chemo) in first line (1L) treatment of patients (pts) with locally advanced (LA), unresectable, or metastatic non-small cell lung cancer (mNSCLC)
19. 1173P Early safety, tolerability, and efficacy of REGN5093 in patients (pts) with MET-altered advanced non-small cell lung cancer (aNSCLC) from a first in human (FIH) study
20. LBA52 Tepotinib + osimertinib for EGFRm NSCLC with MET amplification (METamp) after progression on first-line (1L) osimertinib: Initial results from the INSIGHT 2 study
21. 1109P Amivantamab vs real-world (RW) therapy in Japanese patients with advanced non-small cell lung cancer (aNSCLC) epidermal growth factor receptor (EGFR) exon-20 insertion mutation (E20i)
22. 1302P MET×MET bispecific antibody davutamig (REGN5093) for MET-altered advanced non-small cell lung cancer (aNSCLC): Update from a first-in-human (FIH) study
23. 35P Real-world treatment outcomes of amivantamab in pre-approval access (PAA) participants with advanced non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations (ex20ins)
24. Increased quantity of tumor-infiltrating FOXP3-positive regulatory T cells is an independent predictor for improved clinical outcome in extranodal NK/T-cell lymphoma
25. Class III β-tubulin, but not ERCC1, is a strong predictive and prognostic marker in locally advanced head and neck squamous cell carcinoma
26. Clinical heterogeneity of extranodal NK/T-cell lymphoma, nasal type: a national survey of the Korean Cancer Study Group
27. Efficacy of chemotherapy as a first-line treatment in ocular adnexal extranodal marginal zone B-cell lymphoma
28. 1218P Characterization of GI toxicities and their impact on efficacy in patients (pts) with EGFR exon 20 insertion+ (ex20ins+) non-small cell lung cancer (NSCLC) treated with mobocertinib (TAK-788) who previously received platinum chemotherapy
29. 1364TiP Phase II single-arm trial of safety, antitumor activity, and pharmacokinetics of tusamitamab ravtansine (SAR408701) plus ramucirumab in CEACAM5-positive, metastatic, non-squamous, non-small cell lung cancer progressing on platinum-based chemotherapy and immunotherapy
30. 977P Interim results of phase I dose escalation study of YBL-006: A novel anti-PD-1 monoclonal antibody in advanced solid tumors
31. 529P A phase Ib trial of belvarafenib in combination with cobimetinib in patients (pts) with RAS- or RAF- mutated (m) solid tumors: Updated safety data and indication-specific efficacy results
32. 887P Final results and biomarker analysis from a phase I dose-expansion (part II) study of ISU104 (barecetamab; a novel anti-ErbB3) monotherapy or in combination with cetuximab (CET), in patients (pts) with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)
33. 1231P Characterization and management of mobocertinib (TAK-788) induced skin toxicity in patients with EGFR exon 20 insertion+ (ex20ins+) non-small cell lung cancer (NSCLC) who previously received platinum chemotherapy
34. 566P Safety of tepotinib + osimertinib in EGFR-mutant NSCLC with MET amplification after first-line osimertinib
35. 568P First-line (1L) osimertinib + platinum-pemetrexed in EGFR-mutated (EGFRm) advanced NSCLC: Updated FLAURA2 safety run-in (SRI) results
36. 514MO Acquired mechanisms of resistance to first-line (1L) osimertinib with or without platinum-based chemotherapy (CT) in EGFR-mutated (EGFRm) advanced NSCLC: Preliminary data from FLAURA2
37. LBA67 A phase III, randomized study of atezolizumab plus bevacizumab and chemotherapy in patients with EGFR or ALK mutated in non-small cell lung cancer (ATTLAS, KCSG-LU19-04)
38. 1491P PD-L1 TPS ≥50% predicts durable response after discontinuing immune checkpoint inhibitors in metastatic non-small cell lung cancer patients
39. 1358P Safety of tepotinib + EGFR TKI (osimertinib or gefitinib) in patients with EGFRm NSCLC
40. 1338P Cerebrospinal fluid pharmacokinetic study of lazertinib and pemetrexed in patients with EGFR-mutant non-small cell lung cancer with leptomeningeal metastases: KCSG21-01 LAZARUS trial
41. 1325P Sunvozertinib as first-line treatment in NSCLC patients with EGFR Exon20 insertion mutations
42. 708P Final clinical outcomes of nationwide precision oncology pilot study; KOrean Precision Medicine Networking Group Study of MOlecular profiling guided therapy based on genomic alterations in advanced Solid tumors (KOSMOS) KCSG AL-20-05
43. 2304P A phase II study of tepotinib in patients with advanced solid cancers harboring MET exon 14 skipping mutations or amplification (KCSG AL19 -17)
44. 638P Dacomitinib with or without dose titration in treatment naïve advanced EGFR mutated NSCLC: Primary analysis of the ATORG-003 phase II trial.
45. 366MO Osimertinib plus platinum/pemetrexed in newly diagnosed EGFR mutation (EGFRm)-positive advanced NSCLC: Safety run-in results from the FLAURA2 study
46. 928P Phase I dose-expansion (part II) study of ISU104 (a novel anti-ErbB3 monoclonal antibody) alone and combination with cetuximab (CET), in patients (pts) with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)
47. 1272P Three-year follow-up of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, for second-line (2L) treatment of non-small cell lung cancer (NSCLC)
48. 1401P Osimertinib plus platinum/pemetrexed in newly-diagnosed EGFR mutation (EGFRm)-positive advanced NSCLC: Safety run-in results from the FLAURA2 study
49. O2–027 - Phase 1 Study of MLN8237 (Alisertib) in Adult East Asian Patients (PTS) with Advanced Solid Tumors or Lymphomas
50. Molecular correlates of response to capmatinib in advanced non-small-cell lung cancer: clinical and biomarker results from a phase I trial
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.